Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation
利用新型化合物DYR533抑制Dyrk1a:一种针对淀粉样变性、Tau蛋白发病机制和神经炎症的跨疾病治疗策略
期刊:
影响因子:
doi:10.64898/2026.01.20.700091
Bartholomew, S K; Turk, J; Winslow, W; Foley, C; Shaw, A; Rokey, S; Tallino, S; Judd, M J; Beach, T G; Serrano, G E; Wilms, G; Kushwaha, R; McMahon, A; Ginn, S; Becker, W; Hulme, C; Dunckley, T; Velazquez, R